Demystifying Machine Learning: Why Transparency Will Lead to Trust

05/10/2022 By Andrea

Authored and contributed to PharmaLeaders by Michelle Marlborough, Chief Product Officer, AiCure, LLC Machine learning (ML) innovation for clinical research holds great promise for improving drug development and patient care. But, like with all new technology, increasing prevalence can be accompanied by growing skepticism. Pharmaceutical sponsors and clinicians are understandably suspicious about the value of […]

Pharma join together to achieve new standards in digital and patient innovation for clinical transformation

03/30/2022 By Andrea

On May 17th, 500+ of pharma’s clinical innovation will come together for the home of clinical collaboration, Reuters Events: Pharma Clinical 2022, to set new standards in digital and patient innovation for clinical transformation. The catalyst for this has been the accelerated technological adoption in clinical trials, but a general feeling still that enough isn’t […]

Quoin Pharmaceuticals signs license, distribution agreement with WinHealth Pharma

06/24/2022

This agreement will allow Quoin to offer healthcare professionals and patients in greater China, including Hong Kong, Macau and Taiwan, with access to its products following receipt regulatory The post Quoin Pharmaceuticals signs license, distribution agreement with WinHealth Pharma appeared first … [Read More...]

Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS

06/24/2022

With this FDA approval, IMCIVREE is indicated for chronic weight management in adult and pediatric patients aged six years and older with monogenic or syndromic obesity due to The post Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS appeared first on Pharmaceutical … [Read More...]

FDA approves Ellipses’ application for advanced RET-altered cancer treatment

06/24/2022

EP0031 is a potent next generation selective RET inhibitor (SRI) with broad activity against common RET fusions and mutations, like solvent front resistance mutations. It is jointly developed The post FDA approves Ellipses’ application for advanced RET-altered cancer treatment appeared first on … [Read More...]

FDA approves Novartis’ Tafinlar + Mekinist combination therapy

06/24/2022

The combination therapy is indicated to treat unresectable or metastatic solid tumours with the BRAF V600E mutation in adult and paediatric patients aged six years and above whose The post FDA approves Novartis’ Tafinlar + Mekinist combination therapy appeared first on Pharmaceutical Business … [Read More...]

Featured Article

Demystifying Machine Learning: Why Transparency Will Lead to Trust

Pharma join together to achieve new standards in digital and patient innovation for clinical transformation

White Papers

Mental Health: An Insurance Industry Perspective

Schedule Your Personalized Marketing Technology Workshop

Industry News

Quoin Pharmaceuticals signs license, distribution agreement with WinHealth Pharma

Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS

FDA approves Ellipses’ application for advanced RET-altered cancer treatment

FDA approves Novartis’ Tafinlar + Mekinist combination therapy